Posted on May 31, 2021 by Sitemaster
In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: imaging, PET scan, PyL, Pylarify | 16 Comments »
Posted on April 5, 2019 by Sitemaster
A new article in the most recent issue of the Journal of Urology provides recommendations for clinicians as to the appropriate, current use of “next-generation” imaging in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: imaging, next generation, PET scan, RADAR, recommedndation | 7 Comments »
Posted on February 20, 2011 by Sitemaster
This is hardly a radical new finding but yet another study has recently shown that we are over-using expensive scanning tests in the work-up of patients diagnosed with low- and intermediate-risk prostate cancer — and under-using these tests in men initially diagnosed with high-risk disease. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: bone scan, CT scan, MRI, necessary, PET scan | 1 Comment »
Posted on January 2, 2010 by Sitemaster
A few days ago we suggested that the role of positron emission tomography (PET scanning) as a diagnostic and prognostic tool in patients with prostate cancer was probably best limited to research studies at major medical centers at the present time. A recent study from Germany appears to confirm this suggestion. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: lymph nodes, PET scan, positron emission tomography | 3 Comments »
Posted on March 18, 2009 by Sitemaster
Today we cover reports on:
- The incidence of prostate cancer among older HIV-positive men
- ARTS and the potential of dutasteride in treatment of patients with biochemical recurrence
- PET scans and their use in detection of biochemical recurrence
- Chemotherapy in treatment of prostate cancer … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: ARTS, chemotherapy, dutasteride, HIV, incidence, PET scan | Leave a comment »